First-generation (e.g. glargine 100 units/mL, detemir) and second-generation (e.g. degludec, glargine 300 units/mL) basal insulin analogs provide longer duration of action, more consistent plasma concentrations, and some clinical trials demonstrate a reduced risk of hypoglycemia, compared with intermediate-acting neutral protamine Hagedorn (NPH) insulin [16,17]. This evidence concerns the gene INS and Hypoglycemia.